MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 592534 | Name: Algestone acetophenide
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Algestone acetophenide is a progesterone that has been used in ESTRUS SYNCHRONIZATION and has been evaluated as an injectable contraceptive in combination with estradiol enanthate. It is also used therapeutically as a topical anti-inflammatory and is applied topically in the treatment of ACNE.

Chemical Structure

Algestone acetophenide
CAS# 24356-94-3

Theoretical Analysis

MedKoo Cat#: 592534

Name: Algestone acetophenide

CAS#: 24356-94-3

Chemical Formula: C29H36O4

Exact Mass: 448.2614

Molecular Weight: 448.60

Elemental Analysis: C, 77.65; H, 8.09; O, 14.27

Price and Availability

Size Price Availability Quantity
500mg USD 350.00 2 Weeks
1g USD 550.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
Algestone acetophenide; Neolutin
IUPAC/Chemical Name
R)-16alpha,17-((1-Phenylethylidene)dioxy)pregn-4-ene-3,20-dione
InChi Key
AHBKIEXBQNRDNL-VOAXUGHXSA-N
InChi Code
InChI=1S/C29H36O4/c1-18(30)29-25(32-28(4,33-29)19-8-6-5-7-9-19)17-24-22-11-10-20-16-21(31)12-14-26(20,2)23(22)13-15-27(24,29)3/h5-9,16,22-25H,10-15,17H2,1-4H3/t22-,23+,24-,25-,26+,27+,28?,29-/m1/s1
SMILES Code
CC([C@@]12[C@H](OC(C3=CC=CC=C3)(O2)C)C[C@]4([H])[C@]5([H])CCC6=CC(CC[C@]6(C)[C@@]5([H])CC[C@]14C)=O)=O
Appearance
Solid powder
Purity
>95% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.03.00
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 448.60 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Coutinho EM, Spinola P, Athayde C, Noronha CF, de Melo NR, Cabral ZA, Almeida JA, da Silva BL, Neto JS, Rumi DO. Comparison of two regimens of a monthly injectable contraceptive containing dihydroxyprogesterone acetophenide and estradiol enanthate. Contraception. 2006 Mar;73(3):249-52. Epub 2005 Oct 20. PubMed PMID: 16472564. 2: Coutinho EM, Spinola P, Tomaz G, Morais K, Nassar de Souza R, Sabino Pinho Neto J, de Barros Leal W, Bomfim Hippolito S, D'Aurea Abranches A. Efficacy, acceptability, and clinical effects of a low-dose injectable contraceptive combination of dihydroxyprogesterone acetophenide and estradiol enanthate. Contraception. 2000 Apr;61(4):277-80. PubMed PMID: 10899484. 3: Martínez GH, Castañeda A, Correa JE. Vaginal bleeding patterns in users of Perlutal, a once-a-month injectable contraceptive consisting of 10 mg estradiol enanthate combined with 150 mg dihydroxyprogesterone acetophenide. A trial of 5462 woman-months. Contraception. 1998 Jul;58(1):21-7. PubMed PMID: 9743892. 4: Coutinho EM, Spinola P, Barbosa I, Gatto M, Tomaz G, Morais K, Yazlle ME, de Souza RN, Pinho Neto JS, Leal Wde B, Leal C, Hippolito SB, Abranches AD. Multicenter, double-blind, comparative clinical study on the efficacy and acceptability of a monthly injectable contraceptive combination of 150 mg dihydroxyprogesterone acetophenide and 10 mg estradiol enanthate compared to a monthly injectable contraceptive combination of 90 mg dihydroxyprogesterone acetophenide and 6 mg estradiol enanthate. Contraception. 1997 Mar;55(3):175-81. PubMed PMID: 9115007. 5: Jarquín González JD, Elda de Aguirre L, Rodríguez C, Abrego de Aguilar M, Carrillo F, León DA, Lima M, Trigueros S, Acosta R. Dihydroxyprogesterone acetophenide 150 mg + estradiol enantate 10 mg as monthly injectable contraceptives. Adv Contracept. 1996 Sep;12(3):213-25. PubMed PMID: 8910663. 6: Bassol S, Garza-Flores J. Review of ovulation return upon discontinuation of once-a-month injectable contraceptives. Contraception. 1994 May;49(5):441-53. Review. PubMed PMID: 8045131. 7: Skegg DC. Monthly combined injectable contraceptives and neoplasia. Contraception. 1994 May;49(5):435-9. Review. PubMed PMID: 8045130. 8: Giwa-Osagie OF. Metabolic effects of once-a-month combined injectable contraceptives. The World Health Organization Task Force on Long-Acting Systemic Agents for Fertility Regulation, Geneva, Switzerland. Contraception. 1994 May;49(5):421-33. Review. PubMed PMID: 8045129. 9: Koetsawang S. Once-a-month injectable contraceptives: efficacy and reasons for discontinuation. Contraception. 1994 Apr;49(4):387-98. Review. PubMed PMID: 8013221. 10: Sang GW. Pharmacodynamic effects of once-a-month combined injectable contraceptives. Contraception. 1994 Apr;49(4):361-85. Review. PubMed PMID: 8013220. 11: Toppozada MK. Existing once-a-month combined injectable contraceptives. Contraception. 1994 Apr;49(4):293-301. Review. PubMed PMID: 8013216. 12: Wiemeyer JC, Sagasta CL, Roncales Mateo JM, Lavarello AC, Angel de Toro LA, Salas Diaz R. Multicentred clinical study of the metabolic effect of the monthly injectable contraceptive containing dihydroxyprogesterone acetophenide 150 mg + estradiol enanthate 10 mg. Contraception. 1990 Jul;42(1):13-28. Erratum in: Contraception 1990 Dec;42(6):691. PubMed PMID: 2117515. 13: Thomas DB, Molina R, Rodriguez Cuevas H, Ray RM, Riotton G, Dabancens A, Benavides S, Martinez L, Salas O, Pallet JA, et al. Monthly injectable steroid contraceptives and cervical carcinoma. Am J Epidemiol. 1989 Aug;130(2):237-47. PubMed PMID: 2665476. 14: Garza-Flores J, Alba VM, Cravioto MC, Hernandez L, Perez-Palacios G, Alvarado G, Rivera R, Recio R, Bassol S. Estrogen-progestogen once-a-month injectable contraceptives and serum prolactin. Contraception. 1989 May;39(5):519-29. PubMed PMID: 2524362. 15: Schiavon R, Benavides S, Oropeza G, Garza-Flores J, Recio R, Díaz-Sanchez V, Pérez-Palacios G. Serum estrogens and ovulation return in chronic users of a once-a-month injectable contraceptive. Contraception. 1988 Jun;37(6):591-8. PubMed PMID: 3396358. 16: Recio R, Garza-Flores J, Schiavon R, Reyes A, Diaz-Sanchez V, Valles V, Luz de la Cruz D, Oropeza G, Perez-Palacios G. Pharmacodynamic assessment of dihydroxyprogesterone acetophenide plus estradiol enanthate as a monthly injectable contraceptive. Contraception. 1986 Jun;33(6):579-89. PubMed PMID: 3769482. 17: Osawa S, Betz G, Hall PF. Role of actin in the responses of adrenal cells to ACTH and cyclic AMP: inhibition by DNase I. J Cell Biol. 1984 Oct;99(4 Pt 1):1335-42. PubMed PMID: 6090470; PubMed Central PMCID: PMC2113320. 18: Friedman G. Tixocortol Pivalate (JO 1016). Am J Gastroenterol. 1983 Aug;78(8):529-30. PubMed PMID: 6410909. 19: Larochelle P, Du Souich P, Bolte E, Lelorier J, Goyer R. Tixocortol pivalate, a corticosteroid with no systemic glucocorticoid effect after oral, intrarectal, and intranasal application. Clin Pharmacol Ther. 1983 Mar;33(3):343-50. PubMed PMID: 6402333. 20: Tocornal J, Gómez G. [Estrogens, thrombosis of the splenic vein and bleeding varices of the gastric fundus]. Rev Med Chil. 1982 Aug;110(8):771-3. Spanish. PubMed PMID: 6984208.